Clinical Trials Logo

Apatinib clinical trials

View clinical trials related to Apatinib.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04188847 Completed - Chemotherapy Clinical Trials

First-line Chemotherapy for Recurrent Cervical Cancer

Start date: December 6, 2019
Phase: Phase 2
Study type: Interventional

The response rate of traditional first-line chemotherapy for recurrent or persistent advanced cervical cancer was low. This single arm, open, phase II trial would recruit 37 eligible patients. A combination of cisplatin, paclitaxel and apatinib would be given for first 23 patients. If at least 13 patients achieved complete or partial remission, the same regimen would be given for rest patients. The primary end is overall response rate (ORR). The second ends include progression-free survival, overall survival, disease control rate, remission duration, and adverse events. A molecular testing, mainly consisting of genomic analysis, will be carried in the oncologic tissues.

NCT ID: NCT03365765 Completed - Apatinib Clinical Trials

mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Start date: February 12, 2018
Phase: Phase 3
Study type: Interventional

This study will focus on postoperative patients of stage IIIB or stage IIIC colorectal cancer. These patients will start to accept chemotherapy in 3-4 weeks after operation, these patients were randomly divided into two groups, one group will accept adjuvant chemotherapy of mFOLFOX6; another group will use mFOLFOX6 combined with apatinib. The efficacy and safety of adjuvant chemotherapy will be compared between the two groups. Disease-free survival, overall survival, incidence of adverse reaction of chemotherapy and postoperative quality of life will be recorded.